GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively.
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.

#demand #Manufacturing

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively.
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.

#vaccine

Samuel Monroe Jr. has died after previously being hospitalized for meningitis
He was known for his roles in Menace II Society and The Players Club
"There are no words that can truly express the depth of my heartbreak or the emptiness I feel without you," his wife Shawna Stewart wrote in a tribute
Samuel Monroe Jr. has died after previously being hospitalized for meningitis.
His wife Shawna Stewart shared the news in a Facebook post, stating that he died on Wednesday, Aug. 26, at Providence Saint Joseph Burbank Hospital in California. However, TMZ reported that they received conflicting information from a representative at the hospital, who said he had been discharged alive.

#shawna

Monroe Jr. had been hospitalized due to meningitis, MRSA and pneumonia since April.
Samuel Monroe Jr., an actor known for roles in several Black cinema classics such as "Tales From The Hood," "Menace II Society," and "The Player's Club," has died, his mother confirmed on social media. He was 52.
Monroe had been hospitalized since April for several issues, including MRSA pneumonia and meningitis. He was placed on dialysis to ****** ist with regulating his kidney function. His health had taken a turn in recent weeks, suffering multiple seizures, as doctors suggested he may live the rest of his life in a vegetative state.
"I want to thank all of my facebook family and friends new and old for praying for Samuel Monroe, Jr., my son," his mother, Joyce Patton, wrote on Facebook. "But today God called him home. Please honor my final request to pray for the family especially his 3 children."
In a July update, Monroe's wife, Shawna Stewart wrote on Facebook that he had suffered more than 20 seizures around July 30, leading to swelling around his brain. He'd undergone three brain surgeries, according to Stewart and asked for continued thoughts and prayers for her husband.

#mrsa #samuel #meningitis #pneumonia

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a diagnostics and life sciences supplier still working through the loss of discontinued product lines, beating a cautious bar is one thing. What happens next, as management leans on a stack of new launches to carry the back half of the year, is the more interesting question.
The company's so-called growth pillars, the businesses management is counting on to outpace the broader market, expanded 5% at constant exchange rates in the quarter. Sample Technologies led with 9% CER growth, driven by automated consumables and higher instrument sales. QIAcuity, the digital PCR platform, posted double-digit consumables growth even as weaker OEM demand offset some of that strength. QuantiFERON, the tuberculosis test that had flagged a sharp drop in US immigration testing demand back in the first quarter, still managed to return to growth as demand across other testing groups more than made up the difference.
Behind those numbers sits a wave of product activity. QIAsymphony Connect launched commercially, QIAsprint Connect placements are drawing what management called strong pharma customer acceptance, and two new bloodstream infection panels for QIAstat launched in Europe, detecting 33 pathogens and 28 resistance markers in about an hour, with US FDA approval targeted by year-end. Parse, the single-cell ****** ysis business, is running ahead of its roughly $40 million 2026 sales target and was selected for a NASA-supported research program aboard the International ****** e Station. Qiagen also completed a $500 million share repurchase in January and raised its annual dividend 40% to $0.35 per share.
The flat top line masks uneven performance underneath. Diagnostic solutions overall declined 2% at constant currency, and PCR and nucleic acid amplification sales fell 8%, with QIAstat-Dx down 7% as a tough prior-year comparison in respiratory testing outweighed gains in gastrointestinal and meningitis panels. Profitability also gave ground. Adjusted operating income fell 2% to $157 million, with the margin slipping to 29.4% from 29.9% a year earlier, and adjusted gross margin declined to 66.2% from 66.7% on product mix shifts.
Regionally, EMEA sales fell 2% CER as declines in Germany, France, and Italy outweighed gains elsewhere, and Asia Pacific sales fell 2% CER as China dropped in the low teens, even though it improved sequentially. Inventory days outstanding also climbed to 153 from 149, tied to stockpiling ahead of new launches. The company is now guiding to a jump from roughly negative 1% CER sales growth in the first half to 3% to 4% in the second half, a swing that leans heavily on new products, easier comparisons and the fading drag from discontinued lines all landing on schedule.

#Growth #adjusted #ro

Samuel Monroe Jr. remains on life support in a Los Angeles hospital as his family waits for additional brain scans before making what they have described as an extremely difficult decision about his care.
The 52-year-old actor remains in a medically induced coma after months of serious health complications involving meningitis, MRSA pneumonia and other conditions.
His wife, Shawna Stewart, told TMZ in an August 8th update that Monroe's brain continues to swell and that doctors have warned his family about the possibility that he may not regain meaningful consciousness.
For now, no decision has been announced. Stewart said the family has agreed to wait for several more CT scans before determining how to proceed.
Stewart told TMZ that Monroe's ventricles have become enlarged as his brain continues to swell, contributing to seizures. She said he has undergone three brain surgeries while doctors continue monitoring his condition with CT scans. Monroe is also dealing with serious complications beyond his brain. Stewart said his left lung has partially collapsed.

#remains #decision #complications

LONDON, July 16 (Reuters) - All 15 year-olds in Britain should be offered the vaccine against meningococcal B disease (MenB), an ‌expert committee said on Thursday, changing its previous advice ‌after the country's largest outbreak of the disease earlier this year.
The government will now consider the recommendation before making any changes to national vaccination programmes.
• Two people died in March in a MenB outbreak in Kent, southeast England, which health authorities said was the largest and fastest-growing ‌ever seen in Britain.
• ⁠Adolescents in Britain — as in many other countries — are not routinely vaccinated against meningitis B, but since ⁠2015, the country has offered a vaccine against the disease to babies.
• An independent expert scientific committee was asked to review vaccination plans in the wake of the March outbreak, and has now said ‌teenagers aged about 15 should routinely be offered the vaccine.

The voice behind one of Disney's most beloved characters died at 35 after a hidden battle. Authorities confirmed Daveigh Chase's cause of death, shedding light on her struggles after leaving Hollywood.
The Los Angeles County Department of Medical Examiner revealed Daveigh Chase's official cause of death as Acquired Immunodeficiency Syndrome (AIDS).
The former child actress, legally named Daveigh Schwallier, died on June 16 at the age of 35. The medical examiner's report also notes "chronic polysubstance use" as a significant contributing condition. Authorities classified her death as natural, with Dr. Martina Kennedy overseeing the case.
Chase rose to prominence as the voice of Lilo in Disney's animated hit Lilo & Stitch. She also delivered a memorable performance as Samara in the 2002 horror classic The Ring. Her other credits included Donnie Darko, Big Love, Sabrina the Teenage Witch, ER, and Beethoven's 5th. Her last recorded role came in 2016 for the video game Let It Die.
Her boyfriend, Roy Hernandez, earlier informed TMZ that meningitis and a blood infection caused septic complications. "Behind the scenes, she's faced more than her share of hardship," he shared in a GoFundMe post. He further wrote, "After a difficult childhood and a painful falling out with her family, Daveigh was bullied and struggled to find safety and happiness in downtown LA."

Daveigh Chase, a former child actor known for voicing Lilo in Disney's animated Lilo & Stitch and playing Samara in The Ring, has died. She was 35.
"Daveigh was the sweetest woman on the planet and this is a huge loss to all of us," John Ryan Jr., a representative for Chase, told Yahoo. "Daveigh was one of my best friends for the last 17 years and we've managed her for over a decade. We were in the middle of a documentary about her during this tragic passing."
TMZ was first to report Chase's death. Her boyfriend, Roy Hernandez, told TMZ that she died on Tuesday after battling both meningitis and an infection in her blood. He said it had led to septic shock. Hernandez told the outlet that she was hospitalized for malnutrition earlier in June.
"She was the greatest. She loved cats. She worked with cat rescues with us. She was very to herself, " Ryan told the BBC. "She was not very Hollywood. She'd rather eat at Bob's Big Boy and go home with the cats. She loved acting but wasn't into the fame scene."
Chase began her Hollywood career in a 1998 episode of Sabrina the Teenage Witch. Over the years, she's had guest appearances on numerous TV shows, including CSI, Cold Case and Without a Trace. In 2008, she voiced the main character, Betsy, of Betsy's Kindergarten Adventures, a preschool series. Her longest-running role was Rhonda, a child bride, in the TV series Big Love, which aired from 2006 to 2011.

Daveigh Chase's "devastated" mom has broken her silence after her daughter's shocking death at 35.
Cathy Chase admitted she was in disbelief to learn of her "sunshine" daughter's passing after having no contact with her since 2019.
The former child star, best known for her horrifying portrayal of Samara Morgan in 2002's The Ring, had battled addiction and reportedly lived near Los Angeles' infamous Skid Row.
Her death was announced on Wednesday, June 17, by her boyfriend, Roy Hernandez, who revealed Daveigh died following a battle with meningitis and "several serious blood infections" that led to sepsis.
"I was devastated. It felt like something inside of me squeezing all of the air out of me, and at the same time, it felt like I was exploding outwardly," Cathy told the Daily Mail.

Daveigh Chase's friend and former manager has revealed that the former child actor had been missing for 10 years before her death was announced earlier this week.
Chase, who voiced Lilo in Disney's 2002 animated hit Lilo & Stitch and terrified audiences as Samara Morgan in The Ring the same year, was 35.
The actor's death was announced by her boyfriend, Roy Hernandez, who told TMZ that she died Tuesday after a bout of meningitis and a blood infection that caused septic issues.
Chase's father, John David Schwallier, confirmed the news to The New York Times, adding that his daughter had been homeless and living in Los Angeles with her boyfriend near the hospital where she died. "Him and her were destitute," Schwallier said.
In an interview published Thursday, John Ryan Jr., a Hollywood producer who represented Chase in the last stage of her career, told Entertainment Weekly that the actor disappeared over a decade ago.

Daveigh Chase, a former child actor known for voicing Lilo in Disney's animated Lilo & Stitch and playing Samara in The Ring, has died. She was 35.
"Daveigh was the sweetest woman on the planet and this is a huge loss to all of us," John Ryan Jr., a representative for Chase, told Yahoo. "Daveigh was one of my best friends for the last 17 years and we've managed her for over a decade. We were in the middle of a documentary about her during this tragic passing."
TMZ was first to report Chase's death. Her boyfriend, Roy Hernandez, told TMZ that she died on Tuesday after battling both meningitis and an infection in her blood. He said it had led to septic shock. Hernandez told the outlet that she was hospitalized for malnutrition earlier in June.

Actor Daveigh Chase died on Tuesday. She was 35.
Chase was best known for voicing Lilo Pelekai in the Disney animated film Lilo & Stitch in 2002, and for her terrifying turn as Samara Morgan, the creepy little girl in the horror movie The Ring that same year.
A man claiming to be Chase's boyfriend, Roy Hernandez, told TMZ that the former child star had died from meningitis and an infection in her blood, after being hospitalised in Los Angeles for malnutrition earlier this month.
Just prior to the actor's death, Hernandez set up a GoFundMe in her name, but Chase's longtime manager, John Ryan, repudiated his claims.
"Apparently, a man claiming to be her 'boyfriend' that none of us friends or her family has heard of has set up a GoFundMe. I can confirm Daveigh has a trust account set up at SAG to cover all costs," Ryan told The New York Post.
Chase won an Annie Award for outstanding voice acting in an animated feature production for her turn as Lilo, and went on to lend her voice to several spinoffs, including Stitch! The Movie in 2003, Disney Channel's Lilo & Stitch: The Series also in 2003, and Leroy & Stitch in 2006.

Daveigh Chase, the horror actress who crawled out of a telly in The Ring and who voiced Lilo in Disney's animated Lilo & Stitch, has died aged 35.
Chase, who also starred in the cable drama Big Love, died from sepsis following a bout with meningitis in a Los Angeles hospital, her longtime manager John Ryan Jr confirmed to BBC News on Wednesday.
Ryan said that Chase had been admitted to hospital for malnourishment before her death.
The former child star began acting at 4 years old, booking her first Hollywood job when she was 7, but she retired from acting full time in 2015, he said.
"She was the greatest. She loved cats. She worked with cat rescues with us. She was very to herself, " said Ryan, her friend and manager of 15 years, noting that Chase would often retreat to her home in Las Vegas for years at a time and turn down big studio films to do independent projects.

A former child star known for her work in films such as The Ring and Lilo & Stitch has died. Daveigh Chase was 35.
According to TMZ, Chase died on June 16. The media outlet received confirmation on Chase's devastating death from her boyfriend, Roy Hernandez.
Hernandez told TMZ that Chase died after having an infection in her blood and meningitis, which led to septic issues. In addition, TMZ noted, their sources indicated that Chase had been hospitalized in early June due to malnutrition.
A GoFundMe campaign appears to have been launched by Hernandez shortly before Chase's death. Hernandez wrote, "When we met, I promised to protect her and give her the love and comfort she deserved. Together, we found moments of happiness and hope."
Sadly, he added, her condition had become critical and "the doctors have told me she may not have much time left."

Former child actress Daveigh Chase has died at 35, her boyfriend told TMZ
Chase voiced Lilo in Lilo & Stitch and won an MTV Movie Award for her role as Samara Morgan in The Ring
Chase's death followed a case of meningitis and "several serious blood infections," her boyfriend wrote in a GoFundMe page
Daveigh Chase, the actress who played Samara Morgan in The Ring, has died. She was 35.
Chase, who voiced Lilo in Lilo & Stitch, reportedly died after she contracted meningitis and "several serious blood infections," her boyfriend Roy Hernandez told TMZ, who first reported the news. Her recent health issues resulted in sepsis, he said, which caused her body to shut down.

Daveigh Chase, the young actress best known for "The Ring" and "Lilo & Stitch," has reportedly died. She was 35.
According to TMZ, Chase died June 16 from meningitis and an infection in her blood, her boyfriend Roy Hernandez told the outlet. The outlet reports she was admitted to a Los Angeles hospital earlier this month for malnutrition.
USA TODAY has reached out to Chase's representative for comment.
Chase had her big-screen breakthrough at age 10 co-starring as Jake Gyllenhaal's younger sister, Samantha, in the 2001 psychological thriller "Donnie Darko." She continued to find success as a voice actress: playing the young heroine Chihiro in the English-language dub of Hayao Miyazaki's "Spirited Away," and the misfit Lilo in Disney's 2002 animated hit "Lilo & Stitch."

Daveigh Chase, the actor who voiced Lilo in the animated "Lilo & Stitch" and played Samara in the American horror film "The Ring," has died. She was 35.
Chase's boyfriend, Roy Hernandez, told TMZ that she had been suffering from meningitis, which led to sepsis.
TMZ also reported that Chase was hospitalized in Los Angeles in early June due to malnutrition. Additional details about her death were not immediately available.
The post Daveigh Chase, 'Lilo & Stitch' and 'The Ring' Actress, Dies at 35 appeared first on TheWrap.

Daveigh Chase -- who was the voice of Lilo in Disney's Lilo and Stitch and played Samara in The Ring among her many roles on screen -- died at the age of 35, per reports.
What was Chase's cause of death? TMZ reported that her boyfriend Roy Hernandez said she "died Tuesday from meningitis and an infection in her blood, which caused her to have septic issues and led to her body shutting down." The site also reports she had been in a Los Angeles hospital earlier in June due to "malnutrition."
Sending good thoughts to her family and loved ones.
Per the Cleveland Clinic:
Meningitis makes the protective layers surrounding your brain and spinal cord swell. Bacteria, viruses, fungi, parasites and noninfectious conditions can cause meningitis. Common symptoms include fever, neck stiffness and light sensitivity.

Daveigh Chase, the former child actor who voiced the character of heroic Lilo in 2002's acclaimed Lilo & Stitch and that same year was named Best Villain by MTV Movies Awards for her effectively creepy portrayal of the evil Samara Morgan in The Ring, died Tuesday of complications from meningitis. She was 35.
Her death was announced to TMZ by her boyfriend Roy Hernandez, who had just this week set up a GoFundMe page for the ailing Chase. Hernandez wrote that recently "Daveigh was diagnosed with meningitis and several serious blood infections. Her condition has become critical, and the doctors have told me she may not have much time left."
More from Deadline
Walter Parazaider Dies: Sax Player & Founding Member Of Rock Band Chicago Was 81
William Smithers Dies: 'Dallas,' 'Peyton Place' & 'Papillon' Actor Was 98

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. GSK plc (NYSE:GSK) is one of the most undervalued stocks in the pharma sector.
TheFly reported on May 7 that GSK launched a public health awareness initiative under its Ask2BSure campaign, introducing Julie Bowen and Ty Burrell as campaign advocates to promote education around meningococcal disease, also known as meningitis. The effort encourages parents to better understand infection risks and discuss vaccination with healthcare providers.
The campaign includes an educational video ****** led The Mening-Itinerary, which illustrates everyday teen environments such as dorms, gyms, and social gatherings where bacterial transmission may occur. The content also highlights survivor experiences and aims to address gaps in parental awareness about disease risk and prevention. The initiative is designed to strengthen public understanding of meningitis and support informed vaccination decisions through storytelling and outreach.
Expanding its global commercial footprint, on May 11, GSK plc (NYSE:GSK) entered into an exclusive strategic collaboration with Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group to accelerate the launch and commercialization of bepirovirsen in mainland China. Bepirovirsen is an investigational first-in-class therapy for chronic hepatitis B and is currently under priority regulatory review in China. The partnership combines GSK’s research and development capabilities with CTTQ’s established liver disease franchise and extensive hospital access network across thousands of medical centers.
Under the agreement, CTTQ will manage importation, distribution, and promotional activities in China, while GSK retains global regulatory, safety, and medical oversight responsibilities. The collaboration also includes potential evaluation of select early-stage ****** ets for future partnership opportunities beyond China.